Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Wirth

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
International Journal of Radiation Oncology, Biology, Physics|December 3, 2014
Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trialThomas Wiegel, Detlef Bartkowiak, Dirk Bottke, et al.
Cells|June 2, 2021
Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS LesionsBastian Keck, Angelika Borkowetz, Julia Poellmann, et al.
Molecular Medicine (Cambridge, Mass.)|February 2, 2024
A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancerMichael Rade, Markus Kreuz, Angelika Borkowetz, et al.
European Urology|November 3, 2012
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programmeAxel Heidenreich, Hans-Jörg Scholz, Sebastian Rogenhofer, et al.
The Lancet. Oncology|February 22, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trialFred Saad, Karim Fizazi, Viorel Jinga, et al.
International Journal of Clinical Oncology|September 1, 2019
External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter databaseStefan Zastrow, Laura-Maria Krabbe, Ingmar Wolff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trialCora N Sternberg, Daniel P Petrylak, Oliver Sartor, et al.
Journal of Translational Medicine|June 10, 2010
The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trialMaximilian Burger, Nicolas Thiounn, Stefan Denzinger, et al.
European Urology|April 1, 2014
Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trialThomas Wiegel, Detlef Bartkowiak, Dirk Bottke, et al.
European Urology|February 26, 2019
The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus MeetingManfred Wirth, Nicola Fossati, Peter Albers, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
International Journal of Radiation Oncology, Biology, Physics|December 3, 2014
Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trialThomas Wiegel, Detlef Bartkowiak, Dirk Bottke, et al.
Cells|June 2, 2021
Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS LesionsBastian Keck, Angelika Borkowetz, Julia Poellmann, et al.
Molecular Medicine (Cambridge, Mass.)|February 2, 2024
A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancerMichael Rade, Markus Kreuz, Angelika Borkowetz, et al.
European Urology|November 3, 2012
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programmeAxel Heidenreich, Hans-Jörg Scholz, Sebastian Rogenhofer, et al.
The Lancet. Oncology|February 22, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trialFred Saad, Karim Fizazi, Viorel Jinga, et al.
International Journal of Clinical Oncology|September 1, 2019
External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter databaseStefan Zastrow, Laura-Maria Krabbe, Ingmar Wolff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trialCora N Sternberg, Daniel P Petrylak, Oliver Sartor, et al.
Journal of Translational Medicine|June 10, 2010
The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trialMaximilian Burger, Nicolas Thiounn, Stefan Denzinger, et al.
European Urology|April 1, 2014
Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trialThomas Wiegel, Detlef Bartkowiak, Dirk Bottke, et al.
European Urology|February 26, 2019
The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus MeetingManfred Wirth, Nicola Fossati, Peter Albers, et al.
Pageof 10